Elicio Therapeutics, Inc. - Common Stock — Flux de trésorerie trimestriel (NASDAQ:ELTX) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 28.18 M28.14 M29.53 M28.28 M25.86 M22.69 M Total du passif 39.49 M19.24 M27.69 M24.47 M24.23 M24.13 M Total des capitaux propres -11.31 M8.9 M1.83 M3.82 M1.64 M-1.44 M Total du passif et des capitaux propres 28.18 M28.14 M29.53 M28.28 M25.86 M22.69 M Dette totale 20.03 M09.34 M9.72 M9.41 M9.47 M Dette nette 2.42 M-18.35 M-12.75 M-10.89 M-9.16 M-5.47 M

Nouvelles

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?

H.C. Wainwright relève l’objectif de cours d’Elicio Therapeutics à 17$

H.C. Wainwright raises Elicio Therapeutics price target to $17

Rodman & Renshaw initie la couverture d’Elicio Therapeutics avec une recommandation d’achat

Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating

Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why

Elicio reports antigen spreading in 87% of evaluated cancer patients

Elicio Therapeutics appoints Marc Wolfgang as chief technology officer

Elicio reports strong immune responses in phase 2 KRAS cancer vaccine trial

Elicio’s cancer therapy shows immune response across diverse HLA types